Tearsheet
Investment Highlights Market Valuation Price Chart Return vs. Risk About NTLA Interactive Breakdown Better Bets vs. NTLA Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Intellia Therapeutics (NTLA)

Market Price (10/30/2025): $10.33 | Market Cap: $1.1 Bil
Sector: Health Care | Industry: Biotechnology

Intellia Therapeutics (NTLA)

Market Price (10/30/2025): $10.33
Market Cap: $1.1 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -26%		 Weak multi-year price returns
2Y Excs Rtn is -111%, 3Y Excs Rtn is -155%		 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -512 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -969%
1   Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -792%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -798%
2   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -40%
3   Significant short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 30%
0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -26%
1 Weak multi-year price returns
2Y Excs Rtn is -111%, 3Y Excs Rtn is -155%
2 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -512 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -969%
3 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -792%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -798%
4 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -40%
5 Significant short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 30%

Market Valuation & Key Metrics

NTLAS&P 500
REVENUE GROWTHGOOD
Rev LTM ($ Bil)0.1
Rev Chg Q104.8%6.4%
Rev Chg LTM15.0%5.2%
Rev Chg 3Y Avg6.2%5.3%
PROFITABILITYVERY POOR
Op Inc LTM ($ Bil)-0.5
CFO LTM ($ Bil)-0.4
Net Inc LTM ($ Bil)-0.5
Op Mgn LTM-968.7%18.8%
CFO/Rev LTM-791.9%20.4%
Net Inc Mgn-908.5%12.7%
VALUATIONVERY HIGH
P/S20.33.3
P/CFO-2.615.7
P/FCF-2.521.0
P/E-2.223.7
STABILITYVERY GOOD
Debt/Equity0.100.21
Cash/Assets0.510.07

NTLA Stock

   
   
   
   
   
   
   
Factor Drivers of Stock Movement
The 47.9% change in NTLA stock from 4/30/2025 to 10/29/2025 was primarily driven by a 64.9% change in the company's P/S Multiple.

430202510292025Change
Stock Price ($)8.8713.1247.91%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)57.8852.86-8.67%
P/S Multiple15.6125.7564.92%
Shares Outstanding (Mil)101.87103.73-1.83%
Cumulative Contribution47.86%

LTM = Last Twelve Months as of date shown
The -12.5% change in NTLA stock from 10/29/2024 to 10/29/2025 was primarily driven by a -18.6% change in the company's P/S Multiple.

1029202410292025Change
Stock Price ($)14.9913.12-12.47%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)45.9752.8614.99%
P/S Multiple31.6225.75-18.58%
Shares Outstanding (Mil)96.97103.73-6.97%
Cumulative Contribution-12.90%

LTM = Last Twelve Months as of date shown
The -75.7% change in NTLA stock from 10/30/2022 to 10/29/2025 was primarily driven by a -71.5% change in the company's P/S Multiple.

1030202210292025Change
Stock Price ($)54.0313.12-75.72%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)45.3452.8616.58%
P/S Multiple90.3625.75-71.50%
Shares Outstanding (Mil)75.82103.73-36.81%
Cumulative Contribution-79.01%

LTM = Last Twelve Months as of date shown

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
NTLA Return271%117%-70%-13%-62%13%75%
Peers Return112%-47%-47%-3%-39%47%-48%
S&P 500 Return16%27%-19%24%23%17%110%

Monthly Win Rates [3]
NTLA Win Rate67%42%25%50%33%44% 
Peers Win Rate55%30%43%43%30%58% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
NTLA Max Drawdown-36%-14%-72%-34%-63%-46% 
Peers Max Drawdown-46%-52%-55%-41%-59%-41% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: IONS, CRSP, EDIT, FATE, APM. See NTLA Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/29/2025 (YTD)

How Low Can It Go

Unique KeyEventNTLAS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-86.9%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven663.3%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-39.4%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven65.0%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven56 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-70.2%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven235.1%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven413 days120 days

Compare to IONS, CRSP, EDIT, FATE, APM


In The Past

Intellia Therapeutics's stock fell -86.9% during the 2022 Inflation Shock from a high on 9/3/2021. A -86.9% loss requires a 663.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Intellia Therapeutics (NTLA)

Better Bets than Intellia Therapeutics (NTLA)

 NTLABetter Performance than NTLA
MetricValueIndustry (Biotechnology)
Rev Chg LTM15.0%ALNY (17.2%), INSM (21.2%), INCY (18.1%), NBIX (19.6%), MDGL (3422.0%)
Rev Chg 3Y Avg6.2%AMGN (10.0%), VRTX (11.0%), ALNY (40.8%), INSM (21.6%), UTHR (19.0%)
Op Mgn LTM-968.7%ABBV (23.5%), AMGN (23.5%), GILD (37.4%), VRTX (-1.7%), REGN (26.7%)
CFO/Rev LTM-791.9%ABBV (33.1%), AMGN (34.4%), GILD (34.2%), VRTX (33.7%), REGN (35.6%)
FCF/Rev LTM-798.0%ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), REGN (27.2%)
Total Yield-35.3%ABBV (3.8%), AMGN (7.4%), GILD (7.0%), VRTX (3.4%), REGN (7.2%)
 NTLABetter Performance than NTLA
MetricValueAll Other Sectors
Rev Chg LTM15.0%NVDA (71.6%), MSFT (15.6%), META (19.4%), AVGO (28.0%), PLTR (38.8%)
Rev Chg 3Y Avg6.2%NVDA (92.0%), MSFT (13.2%), GOOGL (10.2%), AMZN (11.3%), META (13.0%)
Op Mgn LTM-968.7%NVDA (58.1%), MSFT (46.3%), AAPL (31.9%), GOOGL (32.7%), AMZN (11.4%)
CFO/Rev LTM-791.9%NVDA (46.6%), MSFT (50.0%), AAPL (26.6%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM-798.0%NVDA (43.6%), MSFT (26.6%), AAPL (23.5%), GOOGL (18.0%), AMZN (2.0%)
Total Yield-35.3%NVDA (1.7%), MSFT (3.2%), AAPL (2.9%), GOOGL (3.8%), AMZN (2.9%)
 Best Bets In Health Care Sector
 NTLARPRX HALO CPRX LNTH PBH PFE INCY EW ILMN HCA
What You Pay           
P/E-2.815.214.212.314.114.112.814.811.711.918.8
P/EBIT-2.78.011.210.59.79.010.311.129.09.910.2
What You Get           
Rev Chg Q104.8%7.7%40.8%19.4%-4.1%-6.6%10.3%20.0%11.9%-4.8%6.4%
Rev Chg LTM15.0%3.0%35.0%28.5%5.7%0.6%13.5%18.1%9.1%-3.3%6.4%
Rev Chg 3Y Avg6.2%0.8%35.5%49.9%34.3%0.8%-12.4%13.1%3.0%-3.0%6.6%
FCF/Rev 3Y Avg-785.0%113.4%43.4%38.9%26.1%21.6%13.8%13.5%11.9%9.0%8.4%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Intellia Therapeutics Stock Lost 6.0%, Buy Or Wait?Return 
2Intellia Therapeutics (NTLA) EBITDA ComparisonFinancials 
3Intellia Therapeutics (NTLA) Net Income ComparisonFinancials 
4Intellia Therapeutics (NTLA) Revenue ComparisonFinancials 
5Intellia Therapeutics (NTLA) Operating Income ComparisonFinancials 
6Intellia Therapeutics (NTLA) Operating Cash Flow ComparisonFinancials 
7Intellia Therapeutics (NTLA) Debt ComparisonFinancials 
8Intellia Therapeutics (NTLA) Tax Expense ComparisonFinancials 
9NTLA Dip Buy Analysis  
10Intellia Therapeutics (NTLA) Stock: 35% of days in last 3 months had 1% or greater fluctuation  
11ARTICLES  
12Market Movers | Winners: ENVB, CODX, SOHO | Losers: NTLA, MAMK, IRBT October 28th, 2025
13Will Intellia Therapeutics Stock Rebound After A 31% Fall In A Month? December 16th, 2022
14Clinical Progress And Depressed Prices Make This Biotech Theme Worth A Look November 28th, 2022
15With Recent Advancements, Are Gene Editing Stocks Worth A Look? August 31st, 2022
16Gene Editing Stocks To Consider After Bluebird Bio’s Breakthroughs June 15th, 2022
Title
0DASHBOARDS
1Market Movers | Winners: ENVB, CODX, SOHO | Losers: NTLA, MAMK, IRBT
2Will Intellia Therapeutics Stock Rebound After A 31% Fall In A Month?
3Clinical Progress And Depressed Prices Make This Biotech Theme Worth A Look
4With Recent Advancements, Are Gene Editing Stocks Worth A Look?
5Gene Editing Stocks To Consider After Bluebird Bio’s Breakthroughs
6ARTICLES
7Intellia Therapeutics Stock Lost 6.0%, Buy Or Wait?
8Intellia Therapeutics (NTLA) EBITDA Comparison
9Intellia Therapeutics (NTLA) Net Income Comparison
10Intellia Therapeutics (NTLA) Revenue Comparison
11Intellia Therapeutics (NTLA) Operating Income Comparison
12Intellia Therapeutics (NTLA) Operating Cash Flow Comparison
13Intellia Therapeutics (NTLA) Debt Comparison
14Intellia Therapeutics (NTLA) Tax Expense Comparison
15NTLA Dip Buy Analysis
16Intellia Therapeutics (NTLA) Stock: 35% of days in last 3 months had 1% or greater fluctuation

Trade Ideas

Select past ideas related to NTLA. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		5.9%5.9%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		16.1%16.1%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		2.6%2.6%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		14.2%14.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		15.2%15.2%-8.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		5.9%5.9%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		16.1%16.1%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		2.6%2.6%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		14.2%14.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		15.2%15.2%-8.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1INBXInhibrx Biosciences144.4%400.3%
2PUMPProPetro92.4%19.0%
3LUMNLumen Technologies56.2%107.2%
4RNAAvidity Biosciences48.6%139.5%
5DYNDyne Therapeutics44.5%0.3%
6ACDCProFrac42.1%-30.4%
7BEBloom Energy41.7%502.0%
8SNDKSanDisk39.1% 
9GTXGarrett Motion36.5%92.3%
10LITELumentum35.6%155.2%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-75.1%5106.3%
2LRNStride-54.1%-32.6%
3VRNSVaronis Systems-47.2%-27.2%
4NTLAIntellia Therapeutics-46.6%12.5%
5FIFiserv-43.6%-65.6%
6ITGRInteger-40.2%-50.7%
7UAMYUnited States Antimony-35.9%374.6%
8AKBAAkebia Therapeutics-29.8%10.5%
9OGNOrganon-29.1%-56.5%
10METCRamaco Resources-27.2%186.6%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PRAXPraxis Precision Medicines269.4%154.4%
2INBXInhibrx Biosciences128.8%400.3%
3PUMPProPetro111.8%19.0%
4NVTSNavitas Semiconductor88.0%280.1%
5FLNCFluence Energy87.8%27.7%
6DYNDyne Therapeutics86.8%0.3%
7VICRVicor83.4%88.7%
8SNDKSanDisk82.1% 
9LUMNLumen Technologies79.7%107.2%
10GLUEMonte Rosa Therapeutics68.7%80.1%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical-61.4%5106.3%
2LRNStride-53.0%-32.6%
3FIFiserv-45.2%-65.6%
4VRNSVaronis Systems-43.7%-27.2%
5OGNOrganon-40.6%-56.5%
6NFENew Fortress Energy-40.3%-91.3%
7VGVenture Global-38.0% 
8ITGRInteger-36.8%-50.7%
9LENZLENZ Therapeutics-34.2%6.1%
10CZRCaesars Entertainment-30.7%-44.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1INBXInhibrx Biosciences144.4%400.3%
2PUMPProPetro92.4%19.0%
3LUMNLumen Technologies56.2%107.2%
4RNAAvidity Biosciences48.6%139.5%
5DYNDyne Therapeutics44.5%0.3%
6ACDCProFrac42.1%-30.4%
7BEBloom Energy41.7%502.0%
8SNDKSanDisk39.1% 
9GTXGarrett Motion36.5%92.3%
10LITELumentum35.6%155.2%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-75.1%5106.3%
2LRNStride-54.1%-32.6%
3VRNSVaronis Systems-47.2%-27.2%
4NTLAIntellia Therapeutics-46.6%12.5%
5FIFiserv-43.6%-65.6%
6ITGRInteger-40.2%-50.7%
7UAMYUnited States Antimony-35.9%374.6%
8AKBAAkebia Therapeutics-29.8%10.5%
9OGNOrganon-29.1%-56.5%
10METCRamaco Resources-27.2%186.6%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Intellia Therapeutics

Financials

NTLAIONSCRSPEDITFATEAPMMedian
NameIntellia.Ionis Ph.CRISPR T.Editas M.Fate The.Aptorum  
Mkt Price13.1271.8862.563.041.341.468.08
Mkt Cap1.411.45.40.30.2-1.4
Rev LTM5371735398-39
Op Inc LTM-512-472-552-161-178--472
FCF LTM-422-563-351-205-119--351
FCF 3Y Avg-396-438-280-182-156--280
CFO LTM-419-502-325-201-116--325
CFO 3Y Avg-387-401-263-177-148--263

Growth & Margins

NTLAIONSCRSPEDITFATEAPMMedian
NameIntellia.Ionis Ph.CRISPR T.Editas M.Fate The.Aptorum  
Rev Chg LTM15.0%-7.6%-82.5%-42.0%-31.2%--31.2%
Rev Chg 3Y Avg6.2%-1.4%380.7%55.3%-15.4%-6.2%
Rev Chg Q104.8%10.1%-597.5%-71.8%-57.4%
QoQ Delta Rev Chg LTM16.0%1.7%0.0%8.6%-36.5%-1.7%
Op Mgn LTM-968.7%-65.9%-1,578.5%-413.4%-2,097.2%--968.7%
Op Mgn 3Y Avg-991.9%-65.7%-678.1%-616.5%-1,295.8%--678.1%
QoQ Delta Op Mgn LTM218.7%1.5%-223.0%164.9%-704.3%-1.5%
CFO/Rev LTM-791.9%-70.0%-927.9%-517.6%-1,365.0%--791.9%
CFO/Rev 3Y Avg-766.0%-59.0%-396.8%-538.7%-887.9%--538.7%
FCF/Rev LTM-798.0%-78.5%-1,001.6%-526.8%-1,402.2%--798.0%
FCF/Rev 3Y Avg-785.0%-64.4%-426.2%-552.8%-908.5%--552.8%

Valuation

NTLAIONSCRSPEDITFATEAPMMedian
NameIntellia.Ionis Ph.CRISPR T.Editas M.Fate The.Aptorum  
Mkt Cap1.411.45.40.30.2-1.4
P/S25.715.9155.66.618.8-18.8
P/EBIT-2.7-30.2-9.9-1.1-0.9--2.7
P/E-2.8-24.9-11.6-1.1-0.9--2.8
P/CFO-3.3-22.7-16.8-1.3-1.4--3.3
Total Yield-35.3%-4.0%-8.6%-92.3%-108.0%--35.3%
Dividend Yield0.0%0.0%0.0%0.0%0.0%-0.0%
FCF Yield 3Y Avg-23.9%-7.0%-6.4%-61.3%-56.9%--23.9%
D/E0.10.10.00.10.5-0.1
Net D/E-0.3-0.1-0.3-0.6-0.9--0.3

Returns

NTLAIONSCRSPEDITFATEAPMMedian
NameIntellia.Ionis Ph.CRISPR T.Editas M.Fate The.Aptorum  
1M Rtn-22.5%12.0%-1.9%-13.6%34.0%-19.8%-7.8%
3M Rtn6.4%65.7%8.5%20.6%17.5%-12.0%13.0%
6M Rtn47.9%134.1%61.8%84.2%4.7%55.5%58.6%
12M Rtn-12.5%81.0%27.8%-2.3%-50.7%2.8%0.3%
3Y Rtn-75.7%61.1%15.2%-76.1%-93.9%-76.5%-75.9%
1M Excs Rtn-27.1%6.9%-6.5%-15.4%3.3%-30.7%-11.0%
3M Excs Rtn4.0%58.5%2.5%12.4%13.1%-14.5%8.2%
6M Excs Rtn24.2%110.3%38.0%60.5%-19.0%31.8%34.9%
12M Excs Rtn-36.4%64.8%13.5%-23.0%-68.1%-30.2%-26.6%
3Y Excs Rtn-154.5%-20.8%-57.3%-154.7%-174.4%-158.6%-154.6%

Comparison Analyses

Title
0Intellia Therapeutics vs. Editas Medicine: Neither Seems Like A Good Bet
1Intellia Therapeutics vs. Ionis Pharmaceuticals: With Return Forecast Of 20%, Ionis Pharmaceuticals Is A Better Bet
2Intellia Therapeutics vs. CRISPR Therapeutics: With Return Forecast Of 49%, CRISPR Therapeutics Is A Better Bet
3Intellia Therapeutics vs. Fate Therapeutics: With Return Forecast Of 74%, Fate Therapeutics Is A Better Bet
4Intellia Therapeutics vs. Steelcase: Neither Seems Like A Good Bet
5Intellia Therapeutics vs. AMC Entertainment: Neither Seems Like A Good Bet
6Intellia Therapeutics vs. CommScope: Neither Seems Like A Good Bet
7Intellia Therapeutics vs. Verint Systems: Neither Seems Like A Good Bet
8Intellia Therapeutics vs. Hanesbrands: Neither Seems Like A Good Bet
9Intellia Therapeutics vs. Progress Software: With Return Forecast Of 27%, Progress Software Is A Better Bet

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/7/20255/8/20252/27/202511/7/20248/8/20245/9/20242/22/202411/9/20238/3/20235/4/20232/23/202311/3/2022
Key Financials Quarterly            
Total Revenue1417139729-21214131413
Ebitda-108-118-134-142-136-111-137-129-130-110-108-104
Operating Income-110-121-136-145-139-114-140-131-132-112-110-106
Net Income-101-114-129-136-147-107-132-122-124-103-113-113
EPS-0.98-1.10-1.27-1.34-1.52-1.12-1.46-1.38-1.40-1.17-1.40-1.49
Key Financials TTM            
Total Revenue TTM534658434653365253535251
Ebitda TTM-502-531-524-528-514-508-506-477-452-418-451-421
Operating Income TTM-512-541-534-538-524-517-515-485-460-426-458-428
Net Income TTM-480-526-519-522-509-486-481-462-453-430-474-442
Growth Rates Quarterly            
Total Revenue Growth104.8%-42.5%771.6%-24.0%-48.8%129.5%-114.1%-9.6%-3.1%12.0%5.6%84.1%
EBITDA Growth21.2%-6.1%2.6%-10.4%-4.8%-1.4%-27.2%-24.4%-34.9%22.9%-37.6%-47.5%
Operating Income Growth20.9%-6.0%2.5%-10.4%-5.1%-1.8%-27.1%-24.2%-34.6%22.4%-36.9%-46.6%
Net Income Growth31.1%-6.4%2.5%-11.0%-18.8%-4.2%-16.5%-7.9%-22.8%29.8%-39.6%-58.0%
Margins Quarterly            
EBITDA Margin-754.8%-711.5%-1039.9%-1560.3%-1961.2%-385.3%--1074.2%-957.5%-871.9%-796.1%-780.8%
Operating Income Margin-772.2%-726.6%-1059.9%-1589.0%-1998.6%-394.0%--1093.3%-973.5%-888.1%-811.1%-795.5%
Net Income Margin-710.8%-687.6%-1001.2%-1489.5%-2112.6%-371.3%--1019.2%-909.8%-818.1%-835.5%-853.5%
Cash & Debt            
Total Cash4605046026586917919128559089341,193828
Total Debt10311921010210611111511812212613198
Net Debt / (Cash)-357-384-391-556-585-680-797-736-786-807-1,062-731
Cash Flows Quarterly            
FCF from Operations-100-149-85-85-58-121-93-101-90-109-90-79
Cash Flows TTM            
FCF from Operations TTM-419-377-349-357-373-405-394-391-368-363-333-298
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC-16.0%-18.0%-20.5%-23.6%-24.2%-21.5%-29.3%-28.7%-30.7%-26.9%-32.6%-36.4%
Return on Invested Capital (ROIC) TTM            
ROIC TTM-18.6%-20.1%-20.1%-21.9%-22.8%-24.4%-27.0%-26.6%-26.7%-25.6%-33.9%-37.0%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Development of genome editing-based therapies3652335843
Total3652335843


Price Behavior

NTLA Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta3.121.902.901.301.531.73
Up Beta3.721.591.731.121.171.30
Down Beta6.282.153.380.781.201.55
Up Capture684%351%581%445%297%678%
Bmk +ve Days13233574144420
Stock +ve Days13223467125352
Down Capture-288%-1%136%139%152%110%
Bmk -ve Days8192952107330
Stock -ve Days7192857124397

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date10152025
Short Interest: Shares Quantity30,904,192
Short Interest: % Change Since 93020253.9%
Average Daily Volume7,353,538
Days-to-Cover Short Interest4.20
Basic Shares Quantity103,732,000
Short % of Basic Shares29.8%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/7/20250.8%-3.3%6.1%
5/8/202513.6%8.1%11.0%
2/27/20250.6%-13.3%-22.2%
11/7/2024-0.4%0.3%-8.3%
8/8/20245.0%0.9%-7.5%
5/9/20248.1%14.0%-1.2%
2/22/20241.1%22.0%2.9%
11/9/2023-12.3%-6.6%2.0%
...
SUMMARY STATS   
# Positive151410
# Negative91014
Median Positive4.8%8.3%8.6%
Median Negative-6.8%-7.0%-9.0%
Max Positive13.6%22.0%59.9%
Max Negative-12.3%-28.3%-25.7%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025807202510-Q 6/30/2025
3312025508202510-Q 3/31/2025
12312024227202510-K 12/31/2024
93020241107202410-Q 9/30/2024
6302024808202410-Q 6/30/2024
3312024509202410-Q 3/31/2024
12312023222202410-K 12/31/2023
93020231109202310-Q 9/30/2023
6302023803202310-Q 6/30/2023
3312023504202310-Q 3/31/2023
12312022223202310-K 12/31/2022
93020221103202210-Q 9/30/2022
6302022804202210-Q 6/30/2022
3312022505202210-Q 3/31/2022
12312021224202210-K 12/31/2021
93020211104202110-Q 9/30/2021

Insider Activity

Expand for More

 

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.